BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 7, 2012--
Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH) today announced that David P. King, Chairman and Chief
Executive Officer, is scheduled to speak at the Barclays Capital 2012
Global Healthcare Conference in Miami Beach, FL. LabCorp’s presentation
is planned for Wednesday, March 14, 2012 at 9:00 a.m. (Eastern Time).
A live audio webcast of the presentation will be available via the
Company Web site at www.labcorp.com
and archived for replay.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is a pioneer in commercializing new diagnostic technologies and
the first in its industry to embrace genomic testing. With annual
revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and
more than 220,000 clients, LabCorp offers more than 4,000 tests ranging
from routine blood analyses to reproductive genetics to companion
diagnostics. LabCorp furthers its scientific expertise and innovative
clinical testing technology through its specialized labs and the LabCorp
Specialty Testing Group: The Center for Molecular Biology and Pathology,
National Genetics Institute, ViroMed Laboratories, Inc., The Center for
Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated
Oncology, DIANON Systems, Inc., Monogram Biosciences, Inc.,
Colorado Coagulation, and Endocrine Sciences. LabCorp conducts clinical
trials testing through its Esoterix Clinical Trials Services. LabCorp
clients include physicians, government agencies, managed care
organizations, hospitals, clinical labs, and pharmaceutical companies.
To learn more about our organization, visit our Web site at: www.labcorp.com.
This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive actions in
the marketplace and adverse actions of governmental and other
third-party payors. Actual results could differ materially from
those suggested by these forward-looking statements. Further information
on potential factors that could affect LabCorp’s financial results is
included in the Company’s Form 10-K for the year ended December 31,
2011, and subsequent SEC filings.
Source: Laboratory Corporation of America(R) Holdings
Investor/Media Contact:
Stephen Anderson, 336-436-5274
www.labcorp.com
